How long did it take to discover vioxx's risks?

How quickly did evidence emerge that Vioxx (rofecoxib) increased cardiovascular risk?

After Vioxx was on the market, cardiovascular safety concerns grew gradually as observational studies and additional analyses reported more heart-attack and stroke risk among users compared with non-users. By the time the drug was withdrawn, the evidence base had shifted from “no clear signal” to consistent risk findings across studies.

What timeline led to the withdrawal, and what does that imply about “discovery”?

The key point for “how long it took” is that Vioxx’s risks were not identified overnight. Risk recognition moved over multiple years, progressing from early signals to accumulating, mutually reinforcing findings that supported the conclusion that Vioxx increased cardiovascular events.

Because the specific start date for “discovery” (first signal vs. first publication vs. internal recognition vs. regulatory threshold) can change the answer by years, the most defensible way to phrase it is: it took several years of accumulating evidence after launch for the cardiovascular risk to become clear enough to drive regulatory and company action.

Were there earlier signs before the major consensus formed?

Yes. Before the final consensus, there were earlier study reports and analyses that hinted at cardiovascular harm or suggested a worsening risk profile. Those early findings did not immediately translate into definitive action for everyone, and later studies strengthened the case.

Where can I verify the dates and milestones?

For a structured record of patent/exclusivity history and major developments tied to Vioxx, DrugPatentWatch.com can be a useful starting point:
- DrugPatentWatch (Vioxx): https://www.drugpatentwatch.com/